CN116139258B - Use of roxburghii SOD in preparing medicine for preventing or treating intestinal diseases - Google Patents

Abstract

The invention provides the application of the roxburgh rose SOD in preparing the medicine for preventing or treating the intestinal diseases, and has important significance for popularization and application of the roxburgh rose SOD.

Description

Use of roxburghii SOD in preparing medicine for preventing or treating intestinal diseases

Technical Field

The present invention relates to the field of food and medicine, and in particular to the use of roxburghii superoxide dismutase (SOD) in the preparation of medicines for preventing or treating intestinal diseases.

Background technique

The roxburghii is the fruit of the plant Rosaceae, also known as Ci Li and Mu Lizi. The fruit skin is densely covered with small fleshy thorns. The mountainous areas of Guizhou and Guangxi are rich in roxburghii, with an annual output of hundreds of thousands of tons. At present, the roxburghii is mainly wild, with a small amount of introduced cultivation. The roxburghii fruit contains amino acids, vitamins, proteins, and minerals such as calcium, potassium, zinc, magnesium, and selenium. The content of superoxide dismutase SOD and VC is extremely high.

Intestinal disease is a general term for a variety of intestinal inflammatory diseases. The clinical manifestations include recurrent abdominal pain and bloating, vomiting blood and bloody stools, diarrhea and constipation, decreased appetite, malnutrition and various systemic complications, which may lead to death in severe cases.

At present, there are few reports on the correlation between sea buckthorn SOD and intestinal diseases, which needs to be studied.

Summary of the invention

The present invention aims to solve at least one of the technical problems existing in the prior art to a certain extent. To this end, the present invention proposes the use of the roxburghii SOD extract in the preparation of a medicament, which is used for preventing or treating intestinal diseases and has important significance for the promotion and application of the roxburghii SOD.

In one aspect of the present invention, the present invention proposes the use of a roxburghii SOD extract in the preparation of a medicament. According to an embodiment of the present invention, the medicament is used to prevent or treat intestinal diseases. The inventors of the present invention have found that the roxburghii SOD extract can improve the colon status and intestinal barrier function of mice, reduce oxidative stress and inflammatory response, and help prevent or treat intestinal diseases.

According to an embodiment of the present invention, the intestinal disease is selected from inflammatory bowel disease.

Inflammatory bowel disease (IBD) is an idiopathic intestinal inflammatory disease with clinical manifestations of diarrhea, abdominal pain, bloody stools, and occurs in the ileum, rectum, and colon, including ulcerative colitis (UC) and Crohn's disease (CD).

According to an embodiment of the present invention, the inflammatory bowel disease is selected from ulcerative colitis. The inventors found that the Rosa roxburghii SOD extract has a good preventive or therapeutic effect on ulcerative colitis.

According to an embodiment of the present invention, the drug is used for at least one of the following: relieving diarrhea or bloody stools, improving shortening of colon length and weight loss, inhibiting spleen swelling, protecting colon tissue integrity, promoting intestinal epithelial cell proliferation, promoting intestinal mucus increase, promoting the production of anti-inflammatory factors in plasma, inhibiting the production of pro-inflammatory factors in plasma, improving intestinal barrier, promoting the production of intestinal barrier proteins in colon epithelial cells and increasing the content of antioxidant enzymes.

According to an embodiment of the present invention, the pro-inflammatory factor is selected from TNF-α, IL-6 and/or IL-1β; the anti-inflammatory factor is selected from IL-4 and/or IL-10; the antioxidant enzyme is selected from glutathione, superoxide dismutase, catalase and/or glutathione peroxidase.

According to an embodiment of the present invention, the method for obtaining the roxburghii SOD extract comprises: transferring an expression vector carrying a nucleic acid encoding roxburghii SOD into yeast, fermenting and culturing to obtain a fermentation broth; subjecting the fermentation broth to a first centrifugation treatment, collecting the supernatant, subjecting the supernatant to a second centrifugation treatment, collecting the supernatant, and obtaining a crude enzyme; filtering the crude enzyme, collecting the filtrate, loading the filtrate onto an agarose gel chromatography column, eluting the agarose gel chromatography column with sodium chloride solutions of different concentrations, collecting the effluent of the target protein, and concentrating to obtain the roxburghii SOD extract. Wherein, the nucleic acid sequence encoding the roxburghii SOD is selected from the nucleotide sequence shown in SEQ ID NO: 2 in the patent application with application number 202111023920.1.

According to the method of the embodiment of the present invention, during the fermentation culture process, yeast can highly express Rosa roxburghii SOD to obtain a fermentation broth containing Rosa roxburghii SOD. The purpose of the first centrifugation is mainly to remove the bacterial body, collect the supernatant, and then perform a second centrifugation to remove impurities to obtain a crude enzyme. The supernatant is filtered to remove impurities, and the resulting filtrate is loaded on agarose gel chromatography for gradient elution, which can further purify Rosa roxburghii SOD. The Rosa roxburghii SOD extract obtained has a high SOD yield, high purity, and high enzyme activity, and more importantly, has a good effect of preventing or treating intestinal diseases.

According to an embodiment of the present invention, the first centrifugal treatment is performed at a speed of 6000-8000 rpm and for a time of 8-15 minutes, so as to remove the bacterial cells.

According to an embodiment of the present invention, the second centrifugal treatment is carried out at a speed of 11000-13000 rpm for 8-15 min, thereby further removing impurities and obtaining a crude enzyme.

According to an embodiment of the present invention, the filtration is performed using a 0.22 μm filter membrane, thereby further removing impurities and facilitating subsequent chromatography treatment.

According to an embodiment of the present invention, the concentration of the sodium chloride solution is 0.15-1 mol/L, and the flow rate of the elution is 0.3-0.8 mL/min. The inventors obtained the above-mentioned optimal elution conditions through a large number of experiments, thereby obtaining a roxburghii SOD extract with high SOD yield, high purity, and high enzyme activity, and more importantly, has a good effect of preventing or treating intestinal diseases.

According to an embodiment of the present invention, a protein purifier is used to detect the composition of the effluent during the elution process, and the effluent when the maximum peak area begins to appear is collected until the peak disappears. The collected effluent is the effluent of the target protein.

According to an embodiment of the present invention, the medicine also contains a pharmaceutically acceptable carrier or adjuvant, such as a carrier, a solvent, a suspending agent or an excipient. Exemplary adjuvants can be liquid or solid, including but not limited to: pH regulators, surfactants, carbohydrates, adjuvants, antioxidants, chelating agents, ionic strength enhancers, preservatives, carriers, glidants, sweeteners, dyes/colorants, flavor enhancers, wetting agents, dispersants, suspending agents, stabilizers, isotonic agents, solvents, emulsifiers, sprays, compressed air or other suitable gases, or other suitable inactive ingredients used in combination with pharmacodynamic compounds. Examples of adjuvants include various lactose, mannitol, oils such as corn oil, buffers such as PBS, saline, polyethylene glycol, glycerol, polypropylene glycol, dimethyl sulfoxide, amides such as dimethylacetamide, proteins such as albumin, monosaccharides and oligosaccharides such as glucose, lactose, cyclodextrin and starch.

The term "treatment" is used to refer to obtaining a desired pharmacological and/or physiological effect, such as improving a disease or condition. The effect may be preventive in terms of completely or partially preventing a disease or its symptoms, and/or may be therapeutic in terms of partially or completely curing a disease and/or the adverse effects caused by the disease. "Treatment" as used herein covers the treatment of mammals, especially humans, including: (a) preventing the occurrence of a disease or condition in individuals who are susceptible to the disease but have not yet been diagnosed with the disease; (b) inhibiting the disease, such as blocking the development of the disease; or (c) alleviating the disease, such as alleviating symptoms associated with the disease. "Treatment" as used herein covers any medication that administers a drug to an individual to treat, cure, alleviate, improve, reduce or inhibit an individual's disease, including but not limited to administering a drug containing the Rosa roxburghii SOD extract described herein to an individual in need.

The term "administration" as used herein refers to the introduction of a predetermined amount of material into a patient by a suitable manner. The medicine of the present invention can be administered by any common route, as long as it can reach the expected tissue. Various modes of administration are expected, including peritoneal, intravenous, intramuscular, subcutaneous, cortical, oral, local, nasal, pulmonary and rectal administration, but the present invention is not limited to these exemplified modes of administration. However, due to oral administration, peptides are digested and peptide bonds are broken, so the active ingredient of the oral administration medicine should be coated or formulated to prevent it from being degraded or destroyed in the stomach. Preferably, the medicine of the present invention can be administered with an injectable preparation. In addition, the medicine of the present invention can be administered using a specific device that transmits the active ingredient to the target cell.

The frequency and dosage of the drug of the present invention can be determined by a number of relevant factors, including the type of disease to be treated, the route of administration, the patient's age, sex, weight and severity of the disease, and the type of drug as the active ingredient. According to some embodiments of the present invention, the daily dose can be divided into 1, 2 or more doses in a suitable form, so that it can be administered once, twice or more times over the entire time period, as long as the therapeutically effective amount is reached.

The term "therapeutically effective amount" refers to an amount of a compound sufficient to significantly improve certain symptoms associated with a disease or condition, that is, an amount that provides a therapeutic effect for a given condition and dosing regimen. For example, in cancer treatment, a drug or compound that reduces, prevents, delays, inhibits or blocks any symptom of a disease or condition should be therapeutically effective. A therapeutically effective amount of a drug or compound does not need to cure a disease or condition, but will provide treatment for the disease or condition so that the onset of the disease or condition in an individual is delayed, stopped or prevented, or the symptoms of the disease or condition are alleviated, or the duration of the disease or condition is changed, or, for example, the disease or condition becomes less severe, or recovery is accelerated.

According to an embodiment of the present invention, the effective dose of the roxburghii SOD extract in the medicine is 4-8 kU/kg mouse body weight/day, or 20-40 kU/60kg human body weight/day.

According to an embodiment of the present invention, the dosage form of the drug is selected from tablets, liquids, powdered preparations, chewable tablets or soft gels.

Beneficial Effects

(1) The Rosa roxburghii SOD extract provided by the present invention can not only effectively inhibit DSS-induced colitis symptoms such as weight loss, diarrhea and bloody stool in mice, but also improve the intestinal barrier function by promoting intestinal epithelial cell proliferation and increasing intestinal mucus.

(2) The roxburghii SOD extract provided by the present invention can open up new drug intervention pathways for improving and treating intestinal diseases including inflammatory bowel disease, diarrhea and bloody stools, and improving intestinal barrier function and intestinal health, which has a significant promoting effect on the application of roxburghii SOD in the market.

Additional aspects and advantages of the present invention will be given in part in the following description and in part will be obvious from the following description, or will be learned through practice of the present invention.

BRIEF DESCRIPTION OF THE DRAWINGS

The above and/or additional aspects and advantages of the present invention will become apparent and easily understood from the description of the embodiments in conjunction with the following drawings, in which:

Figure 1 is a comparison diagram of the experimental design, mouse weight change, disease activity index, mouse physical picture, spleen organ coefficient, and colon length of the PBS group, DSS group, and CL_SOD group in Example 2;

FIG2 is a comparison of the pathological status of the colon tissues of mice in the PBS group, the DSS group and the CL_SOD group in Example 3, wherein the scale of the staining diagram is 100 μm;

FIG3 is a comparison of AB-stained goblet cells (GCS) in colon tissue of mice in the PBS group, DSS group, and CL_SOD group in Example 4, wherein the scale of the staining image is 100 μm;

FIG4 is a comparison of PAS-stained mucus in colon tissue of mice in the PBS group, the DSS group, and the CL_SOD group in Example 5, wherein the scale of the staining image is 100 μm;

FIG5 is a comparison of the antioxidant content in plasma of mice in the PBS group, the DSS group and the CL_SOD group in Example 6;

FIG6 is a comparison chart of the levels of inflammatory factors in the plasma of mice in the PBS group, DSS group, and CL_SOD group in Example 7.

Detailed ways

The scheme of the present invention will be explained below in conjunction with the embodiments. It will be appreciated by those skilled in the art that the following embodiments are only used to illustrate the present invention and should not be considered as limiting the scope of the present invention. Where specific techniques or conditions are not indicated in the embodiments, the techniques or conditions described in the literature in this area or the product specifications are used. The reagents or instruments used are not indicated by the manufacturer and are all conventional products that can be obtained commercially.

Example 1

In this embodiment, the roxburghii SOD extract was obtained according to the following method:

1. Referring to steps 1 and 2 of Example 1 in the patent application with application number 202111023920.1, a fermentation broth containing roxburghii SOD was prepared;

2. Centrifuge the fermentation broth at 7000 rpm for 15 min, collect the supernatant, and then centrifuge at 12000 rpm for 15 min to collect the supernatant to obtain the crude enzyme;

3. The crude enzyme was filtered through a 0.22 μm filter, and the filtrate was loaded onto a Capto Q agarose chromatography column (GE Healthcare, Sweden). It was eluted with a linear gradient of 0.15-1 mol/L NaCl solution at a flow rate of 0.5 mL/min. The entire elution process was carried out at 4°C. The effluent was detected by an AKTA protein purifier. When the peak with the largest peak area appeared, the effluent was collected until the peak was finished. The effluent was concentrated to obtain a Rosa roxburghii SOD extract with a purity of over 99.99% and a SOD specific activity of over 13,000 U/mg.

Example 2: Rosa roxburghii SOD can improve inflammatory bowel disease in mice

Dextran Sulfate Sodium (DSS)-induced colitis in mice was used as a research model. The model was established as follows: 6-week-old healthy male C57BL/6J mice were selected and raised in a standard 12-hour day and night cycle, 22°C constant temperature, and a specific pathogen-free (SPF) environment. After one week of adaptive feeding, the mice were randomly divided into a normal group (PBS, 8 mice), a model group (DSS, 8 mice), and a roxburghii SOD group (CL_SOD+DSS, 8 mice). After one week of adaptive feeding, the PBS group and the DSS group were gavaged with 0.1 mol/L PBS (0.1 ml/10 g (mouse body weight)/day), and the CL_SOD group was gavaged with the roxburghii SOD extract obtained in Example 1 (7.5 kU/kg (mouse body weight)/day). After continuous gavage for 3 weeks, 2.5% DSS was added to the drinking water of the three groups of mice, and the mice were allowed to drink water freely for 7 consecutive days to induce colitis. During the induction process, the weight, fecal status, and blood in the stool of the mice were recorded daily. After the experiment, the eyeballs were removed and blood was collected in EDTA anticoagulant centrifuge tubes. After static centrifugation, plasma was obtained. The mice were dissected, and the colon and spleen were removed. The colon length was measured, the spleen was weighed, and photos were taken. The colon contents were collected, and 2 mm colon tissue samples were preserved with 4% formalin fixative. The remaining colon tissues were collected in cryopreservation tubes and frozen in liquid nitrogen. After the dissection, the colon tissue and intestinal contents were transferred to a -80°C refrigerator for storage.

The changes in the symptoms of inflammatory bowel disease in the three groups of mice treated with different treatments, PBS, DSS, and CL_SOD, are shown in Figure 1. Figure 1a shows the experimental design process. Figure 1b shows the weight change trend of mice after IBD modeling. It can be seen that 3 days after DSS induction, the weight of mice in the DSS group decreased significantly compared with the mice in the PBS group. After 7 days of induction, the average weight of mice in the DSS group was 82.21±9.78% of the initial weight, and the average weight of mice in the CL_SOD group was 88.17±4.34% of the initial weight, with a significant difference of p<0.01. This shows that Rosa roxburghii SOD can significantly alleviate the weight loss of mice induced by DSS.

The disease activity index (DAI) is an important indicator for evaluating the severity of the colitis model by combining parameters such as weight loss, stool looseness, and blood in the stool. The comparative data of the disease activity index (DAI) of the three groups of mice are shown in Figure 1c. The higher the DAI score, the more severe the diarrhea and blood in the stool of the mice. Figure 1d is a comparison of the photos taken before the mouse dissection. Combining the two figures, it can be seen that compared with the DSS group mice, the DAI of the CL_SOD group mice gavaged with Rosa roxburghii SOD was significantly reduced, that is, the symptoms of colitis in the mice were significantly improved, indicating that Rosa roxburghii SOD can significantly improve the disease activity index of DSS-induced mice.

The spleen is the largest immune organ of mice. The spleen coefficient (ratio of spleen weight to body weight) can effectively reflect the immune response and attenuation function of mice to foreign substances. It is also a commonly used indicator in toxicological experiments. The comparison of spleen coefficients of the three groups of mice is shown in Figure 1e. Combining the photos of mouse spleens with the statistical data, it can be seen that compared with the DSS group mice, the DAI of the CL_SOD group mice gavaged with Rosa roxburghii SOD, that is, the mouse spleen coefficient, was significantly reduced, indicating that Rosa roxburghii SOD can significantly improve the immune response and attenuation function of mice induced by DSS.

Colon length is another important reference indicator for evaluating the severity of colon inflammation. As shown in Figure 1f, combined with the colon length photos and colon data comparison charts of mice, it can be seen that compared with the DSS group mice, the colon length of the CL_SOD group mice gavaged with Rosa roxburghii SOD was longer, that is, Rosa roxburghii SOD can significantly improve the inflammatory symptoms such as shortened colon length, congestion and edema induced by DSS.

As shown in Figure 1, Rosa roxburghii SOD can effectively inhibit DSS-induced weight loss, diarrhea and bloody stools in mice, and relieve symptoms such as shortened colon and swollen spleen.

Example 3: Rosa roxburghii SOD can promote colon pathology in healthy mice

The DSS-induced colitis in mice in Example 2 was used as a research model to explore the effect of Rosa roxburghii SOD on the pathological state of the colon tissue of mice. The colon pathological state of mice was detected by hematoxylin/eosin (H&E) staining. Specifically as shown in Figure 2, a, b, and c of Figure 2 are comparison diagrams of intestinal epithelial tissues of three groups of mice, and d, e, and f of Figure 2 are data comparison diagrams of the thickness of the colon mucosa layer, the depth of the colon crypts, and the colon histopathological scores of three groups of mice. As can be seen from Figure 2, compared with the mice in the DSS group, the mice in the CL_SOD group that were gavaged with Rosa roxburghii SOD showed significantly improved colon pathological state.

Example 4: Rosa roxburghii SOD can promote the proliferation of intestinal epithelial goblet cells in healthy mice

Goblet cells are a special type of intestinal epithelial cells that can produce and secrete mucin into the intestinal cavity to form a mucus layer to maintain intestinal barrier function and prevent excessive immune activation. Using DSS-induced colitis in mice in Example 2 as a research model, the effect of Rosa roxburghii SOD on the proliferation of intestinal epithelial goblet cells in mice was explored. The morphological changes of mouse colon epithelial goblet cells were detected by periodic acid-Schiff (PAS) staining. Image J was used to quantitatively analyze the results of PAS staining for GCs.

As shown in Figure 3, a, b, and c of Figure 3 are comparison diagrams of intestinal epithelial goblet cells in three groups of mice, and d of Figure 3 is a data comparison diagram of the area percentage of intestinal epithelial goblet cells in three groups of mice. As can be seen from Figure 3, compared with the mice in the DSS group, the mice in the CL_SOD group gavaged with Rosa roxburghii SOD showed a significant promotion of intestinal epithelial goblet cell proliferation.

Example 5: Rosa roxburghii SOD can promote intestinal mucus production in healthy mice

The mucus layer has the important function of preventing intestinal bacteria and other pathogenic antigens from entering the blood circulation and other tissues and organs of the body. Using the DSS-induced colitis in mice in Example 2 as a research model, the effect of Rosa roxburghii SOD on intestinal mucus production in mice was explored. The changes in colon mucus production in mice were analyzed using Alcian Blue (AB) staining.

As shown in Figure 4. Figure 4 a, b, c are the actual comparison pictures of the colon mucus barrier of the three groups of mice, and Figure 4 d is the comparison picture of the area percentage of the colon mucus layer of the three groups of mice. As can be seen from Figure 4, compared with the mice in the DSS group, the mice in the CL_SOD group gavaged with Rosa roxburghii SOD showed significantly increased mucus.

Therefore, sea buckthorn SOD has the function of promoting intestinal epithelial cell proliferation and increasing intestinal mucus, which has an important influence on the body's intestinal anti-infection and immune functions, and thus plays an important role in the occurrence and development of various intestinal diseases such as inflammatory bowel disease, cystic fibrosis, and intestinal tumors.

Example 6: Rosa roxburghii SOD can enhance antioxidant capacity and alleviate oxidative damage

The IBD model constructed using DSS will cause the colonic lesions to produce a large number of free radicals, which will lead to oxidative damage in the colon. The DSS-induced colitis in mice in Example 2 was used as a research model to explore the effect of Rosa roxburghii SOD on alleviating oxidative damage in mice. A commercial kit (Solarbio, Beijing, China) was used to detect representative oxidoreductases in plasma, such as total antioxidant capacity (T-AOC), propylene glycol (MDA), glutathione (GSH), superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPX).

As shown in Figure 5. Figure 5 a~f are comparison charts of T-AOC, MDA, GSH, SOD, CAT and GPX content in the plasma of the three groups of mice. It can be seen from Figure 5 that compared with the DSS group mice, the plasma content of antioxidant enzymes (glutathione, superoxide dismutase, catalase, glutathione peroxidase) in the CL_SOD group mice gavaged with roxburghii SOD was increased, and the content of peroxidation products (propylene glycol) was reduced. Therefore, roxburghii SOD can enhance the antioxidant capacity of mouse colon and alleviate oxidative damage.

Example 7: Rosa roxburghii SOD can enhance the anti-inflammatory ability of mice and relieve inflammatory damage

Inflammatory response is an important indicator of IBD. The DSS-induced IBD mice in Example 2 were used as a model to explore the effect of Rosa roxburghii SOD on alleviating inflammatory damage in mice. The concentrations of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), interleukin-1β (IL-1β), interleukin-4 (IL-4) and interleukin-10 (IL-10) in mouse plasma were detected by ELISA (Shanghai ELISA Biotechnology Co., Ltd.).

As shown in Figure 6. Figure 6 a~e are the concentrations of TNF-α, IL-6, IL-1β, IL-4 and IL-10 in the plasma of the three groups of mice. As can be seen from Figure 6, compared with the mice in the DSS group, the concentrations of the inflammatory factors TNF-α, IL-6 and IL-1β in the plasma of the mice in the oral CL_SOD group were significantly reduced, and the concentrations of the inflammatory factors IL-4 and IL-10 were significantly increased. This shows that Rosa roxburghii SOD can enhance the anti-inflammatory ability of mice and relieve inflammatory damage.

In the description of this specification, the description with reference to the terms "one embodiment", "some embodiments", "example", "specific example", or "some examples" etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representations of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art may combine and combine the different embodiments or examples described in this specification and the features of the different embodiments or examples, without contradiction.

Although the embodiments of the present invention have been shown and described above, it is to be understood that the above embodiments are exemplary and are not to be construed as limitations of the present invention. A person skilled in the art may change, modify, replace and vary the above embodiments within the scope of the present invention.

Claims (7)

1. Use of a roxburghii SOD extract in preparing a medicament, wherein the medicament is used to prevent or treat intestinal diseases, and the intestinal diseases are selected from ulcerative colitis; The method for obtaining the roxburghii SOD extract comprises: The expression vector carrying the nucleic acid encoding the roxburghii SOD is transferred into yeast, and fermented to obtain a fermentation liquid; The fermentation broth is subjected to a first centrifugation treatment to collect a supernatant, and the supernatant is subjected to a second centrifugation treatment to collect a supernatant to obtain a crude enzyme; The crude enzyme is filtered, the filtrate is collected, the filtrate is loaded onto an agarose gel chromatography column, the agarose gel chromatography column is eluted with sodium chloride solutions of different concentrations, the effluent of the target protein is collected, and the effluent is concentrated to obtain the roxburghii SOD extract; The first centrifugal treatment is performed at a speed of 6000-8000 rpm and a time of 8-15 min; The second centrifugal treatment is performed at a speed of 11000-13000 rpm for 8-15 min; The filtration was performed using a 0.22 μm filter membrane; The concentration of the sodium chloride solution is 0.15-1 mol/L; The flow rate of the elution is 0.3-0.8 mL/min; The composition of the effluent during the elution process is detected by a protein purifier, and the effluent at the beginning of the maximum peak area is collected until the peak disappears. The collected effluent is the effluent of the target protein. 2. The use according to claim 1, characterized in that the drug is used for at least one of the following: Relieve diarrhea or bloody stools, improve shortening of colon length and weight loss, inhibit spleen swelling, protect colon tissue integrity, promote intestinal epithelial cell proliferation, promote increase in intestinal mucus, promote the production of anti-inflammatory factors in plasma, inhibit the production of pro-inflammatory factors in plasma, improve intestinal barrier, promote the production of intestinal barrier proteins in colon epithelial cells and increase the content of antioxidant enzymes. 3. The use according to claim 2, characterized in that the pro-inflammatory factor is selected from TNF-α, IL-6 and/or IL-1β; The anti-inflammatory factor is selected from IL-4 and/or IL-10; The antioxidant enzyme is selected from glutathione, superoxide dismutase, catalase and/or glutathione peroxidase. 4. The use according to claim 1, characterized in that the medicine further contains a pharmaceutically acceptable excipient. 5. The use according to claim 1, characterized in that the effective dose of the Rosa roxburghii SOD extract in the medicine is 4-8 kU/kg mouse body weight/day, or 20-40 kU/60kg human body weight/day. 6. The use according to claim 1, characterized in that the dosage form of the drug is selected from tablets, liquids, powdered granules or soft gels. 7. The use according to claim 1, characterized in that the dosage form of the drug is selected from chewable tablets.